Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma
Latest Information Update: 10 Jun 2024
Price :
$35 *
At a glance
- Drugs Panobinostat (Primary) ; Busulfan; Gemcitabine; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 04 Jun 2024 Status changed from active, no longer recruiting to completed.
- 28 May 2024 Planned End Date changed from 30 Aug 2024 to 30 Aug 2025.
- 28 May 2024 Planned primary completion date changed from 30 Aug 2024 to 30 Aug 2025.